Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Santaris Pharma Partners with Bristol-Myers Squibb

Published: Wednesday, April 24, 2013
Last Updated: Wednesday, April 24, 2013
Bookmark and Share
Santaris Pharma announces a worldwide discovery alliance with Bristol-Myers Squibb to discover and develop novel RNA-targeted medicines.

Under the terms of the agreement, Santaris Pharma will receive an upfront payment of $10 million, up to $90 million in potential milestone payments per product and funding of ongoing discovery and research activities. In addition, Santaris Pharma will be eligible to receive royalties on the worldwide sales of all medicines arising from the alliance.

Announcing the alliance, President and CEO of Santaris Pharma, Henrik Stage, said: "We are delighted to welcome Bristol-Myers Squibb as a new partner. This strategic alliance further consolidates Santaris Pharma’s leadership in the field of oligonucleotide therapeutics."

Dr Henrik Ørum, Santaris Pharma’s Chief Scientific Officer and VP Business Development commented: "We are proud and honored that Bristol-Myers Squibb has chosen Santaris Pharma as their partner. We are confident that the unique features of the LNA Drug platform can achieve clinical breakthroughs and look forward to working closely with the Bristol-Myers Squibb team."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Santaris and miRagen Expand Partnership in the Field of Drugs Against microRNAs
miRagen receives license to develop a further six LNA drugs.
Wednesday, January 16, 2013
Santaris Delivers Six LNA-Based RNA Inhibitors to Enzon Ahead of Schedule
Santaris announces completion of the delivery of six cancer target drug candidates to its collaboration partner Enzon.
Tuesday, April 28, 2009
Santaris Pharma Begins Human Clinical Testing of the World’s First Medicine Targeted at a Human microRNA
SPC3649 (LNA-antimiR-122) being developed as a potential new therapy for Hepatitis C virus (HCV) infection.
Wednesday, May 28, 2008
Nature Publishes Study by Santaris Pharma Scientists and Collaborators
The paper demonstrates microRNA silencing in non-human primates, providing a validation of Santaris Pharma’s clinical program to develop a LNA-based therapeutics.
Friday, March 28, 2008
Santaris Pharma Awarded €1.35M by Denmark’s Advanced Technology Foundation
Santaris Pharma has been awarded the grant towards the development of the first ever drug targeted against a human microRNA.
Wednesday, July 04, 2007
Santaris Pharma Raises EUR 40 M of new Equity
The funds will enable the further development of Santaris Pharma’s platform for LNA-based human therapeutics.
Friday, March 17, 2006
Scientific News
Early Genetic Changes in Premalignant Colorectal Tissue Identified
Findings point to drivers of early cancer development, targets for cancer prevention therapies.
Scientists Find Evidence That Cancer Can Arise Changes
Researchers at Rockefeller University have found a mutation that affects the proteins that package DNA without changing the DNA itself can cause a rare form of cancer.
Breakthrough Approach to Breast Cancer Treatment
Scripps scientists have designed a drug candidate that decreases growth of breast cancer cells.
A Guide to CRISPR Gene Activation
A comparison of synthetic gene-activating Cas9 proteins can help guide research and development of therapeutic approaches.
Testing Non-Breast/Ovarian Cancer Genes
Researchers have found that expanding gene panel beyond breast/ovarian cancer genes in these patients does not add any clinical benefit. Instead, testing has produced more questions than answers.
Myeloid-Derived Suppressor Cells Play Role in Tumor Growth
Researchers at Baylor College of Medicine have reported a new mechanism that helps cancer cells engage myeloid-derived suppressor cells.
Cancer Cells Coordinate to Form Roving Clusters
Rice University scientists identify ‘smoking gun’ in metastasis of hybrid cells.
Poliovirus Therapy Wins 'Breakthrough' Status
FDA decision will fast-track research on breakthrough Duke brain cancer therapy.
Novel Way to Prevent Deadly Bacterial Infections
Monash scientists may have found a way to stop deadly bacteria from infecting patients. The discovery could lead to a whole new way of treating antibiotic-resistant “superbugs”
New Treatment for Pancreatic Cancer
Researchers at Purdue University have shown how controlling cholesterol metabolism in pancreatic cancer cells reduces metastasis.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!